June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Rho-kinase involvement in ocular fibrosis
Author Affiliations & Notes
  • Yuebing Li
    Ophthalmology, Inselspital Universitatsspital Bern, Bern, Bern, Switzerland
    Graduate School for Cellular and Biomedical Sciences, Universitat Bern, Bern, Bern, Switzerland
  • Laura Jahnka
    Ophthalmology, Inselspital Universitatsspital Bern, Bern, Bern, Switzerland
    Graduate School for Cellular and Biomedical Sciences, Universitat Bern, Bern, Bern, Switzerland
  • Ali Hafezi-Moghadam
    Molecular Biomarkers Nano-Imaging Laboratory, Brigham and Women's Hospital, Radiology Department, Harvard Medical School, Boston, Massachusetts, United States
  • Volker Enzmann
    Ophthalmology, Inselspital Universitatsspital Bern, Bern, Bern, Switzerland
    Graduate School for Cellular and Biomedical Sciences, Universitat Bern, Bern, Bern, Switzerland
  • Martin Sebastian Zinkernagel
    Ophthalmology, Inselspital Universitatsspital Bern, Bern, Bern, Switzerland
  • Souska Zandi
    Ophthalmology, Inselspital Universitatsspital Bern, Bern, Bern, Switzerland
  • Footnotes
    Commercial Relationships   Yuebing Li None; Laura Jahnka None; Ali Hafezi-Moghadam None; Volker Enzmann None; Martin Zinkernagel Novartis (C), Code C (Consultant/Contractor), Roche (C), Code C (Consultant/Contractor), Zeiss (C), Code C (Consultant/Contractor), Bayer (C,F), Code C (Consultant/Contractor), Boehringer Ingelheim (F), Code F (Financial Support); Souska Zandi None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 5464. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yuebing Li, Laura Jahnka, Ali Hafezi-Moghadam, Volker Enzmann, Martin Sebastian Zinkernagel, Souska Zandi; Rho-kinase involvement in ocular fibrosis. Invest. Ophthalmol. Vis. Sci. 2023;64(8):5464.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Ocular fibrosis is not only a chronic process responsible for the pathogenesis or treatment failure of many blinding eye diseases but also one of the important causes of irreversible visual impairment in patients. CNV-related subretinal fibrosis in age-related macular degeneration (AMD), fibrovascular membranes in diabetic retinopathy (DR), proliferative vitreoretinopathy (PVR) and epiretinal membranes (ERM) may limit the long-term visual prognosis of affected patients. To date, only very limited successful treatment for ocular scarring exists. We aim to investigate the impact of anti-fibrotic compounds on ocular fibrosis. Therefore we examined in a time-dependent subretinal fibrosis animal model the effect of rho-kinase (ROCK) isoform specific inhibition on ocular fibrosis.

Methods : To induce CNV-related fibrosis, we used a 532-nm laser inserted in a slit-lamp delivery system. After the development of fibrosis on day 35, 8-9 week old mixed gender C57BL/6 mice were treated intraperitoneally every day with fasudil ( pan ROCK inhibitor ) or belosumodil ( ROCK2 inhibitor ) for two weeks. We performed optical coherence tomography (OCT), autofluorescence and fluorescence angiography every week after laser injury ( d7,14,21,28,35,42,49, n=6 mice per timepoint ) to document fibrotic changes over time. In addition, we screened choroidal flat mounts, western blot and eye sections for CNV and fibrosis.

Results : From day 21 to day 49 after laser injury of mice eyes CNV and leakage decreased and subretinal fibrosis increased in OCT and fluorescence angiography. The expression of type 1 collagen in lesions of choroidal flat mounts increased, whereas isolectin B decreased. CNV reaches a maximum on days 7 to 14, after which it regresses and almost completely disappears from 21 to 35 days post-laser when fibrosis increases. After treatment, fibrosis volume decreased, and both ROCK inhibitors substantially reduced subretinal fibrosis in vivo. In addition, type 1 collagen in flatmounts and western blot of the RPE-choroid complex decreased with ROCK inhibition.

Conclusions : The current results indicate that rho-kinase might play a role in ocular fibrosis. The ROCK inhibitors fasudil and belosumodil may have therapeutic potential for the treatment of subretinal fibrosis in neovascular age-related macular degeneration and other ocular scarring diseases.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×